40, P=0.02) and higher AFP(>5ng/ml) level (HR 4.33, P=0.032). In a multivar-iate

analysis, older age (>60 years) at SVR24 was identified Cytoskeletal Signaling inhibitor to be an independent variable of the development of HCC (HR 15.93, P=0.0046). Conclusions SVR patients of older (>60 years old) age at SVR24 require careful assessments to detect early HCC development after IFN therapy. In patients with HCV infection, viral eradication of younger age should be needed to prevent HCC development after IFN therapy. Disclosures: The following people have nothing to disclose: Masafumi Naito Background and Aim: Controlled randomized clinical trials demonstrated thyroid dysfunction in up to 20% of patients undergoing interferon-based therapies for chronic HCV infection. Data regarding the frequency and severity of these alterations caused by triple therapy are still scarce and were evaluated in the JQ1 nmr present analysis by comparison of two German real-life cohorts. Methods: Data of 1436 patients treated for G1 infection with pegylated

interferon (PegIFN) alfa-2b and ribavirin (RBV) in a large German observational study (Online-AWB) were compared with data of 233 patients from the ongoing German NOVUS observational study who have started triple therapy with PegIFN/RBV together with boce-previr (BOC) at least 8 months ago. Thyroid dysfunction was estimated by serum TSH levels. TSH levels below or above the normal range were classified as abnormal. Results: After starting dual therapy 304/1436 (21.2%) patients developed abnormal TSH values. TSH abnormalities were associated with female gender as indicated by a significantly (p<0.0001) higher incidence of 26.5% (160/603) in female subjects in contrast to 16.9% (136/807) in male subjects. During BOC triple therapy 46/233 (19.7%) experienced abnormal TSH values which was not different in comparison to dual therapy (p=0.62). Again, TSH abnormalities occurred more frequently in female patients (33.3%, 33/99; p<0.0001) than in male patients (9.7%, 13/134). Under triple therapy the majority

of patients (93.5%, 43/46) experienced abnormal TSH values above the normal range indicative for hypothyroidism. Of MCE公司 these 20 patients (46.5%) were substituted with levothyroxine. Until now no patient discontinued BOC triple therapy because of thyroid dysfunction. Regarding virologic response, 69.5% (116/167) of patients with normal TSH values achieved an early virology response in treatment week 8 in contrast to 51.3% (20/39) in patients who experienced elevated TSH levels (p=0.031). Conclusions: Compared to dual therapy of genotype 1 infection there is no increase in the frequency of thyroid dysfunctions during BOC triple therapy. Hypothyroid-ism triggered by PegIFN seems to be associated with a lower EVR response which needs further investigation.